RecruitingMajor Depressive Disorder
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Sponsor: Neurocrine Biosciences
Where it's recruiting
Alabama
Huntsville
California
Glendale · Irvine
Florida
Miami · Tampa
Georgia
Atlanta
Massachusetts
Boston
Missouri
Saint Charles
New York
The Bronx
Ohio
Mason
Source: ClinicalTrials.gov · NCT06911112 · last updated 2025-12-01